K-252a (C15-1295-212)

Catalog No.: C15-1295-212
Manufacturer No.: K1639-100UG
Manufacturer Name: Sigma-Aldrich
Quantity: 100
Unit of Measure: UG

Price: $413.27

List Price: $459.18

Application K-252a has been used: as a tropomyosin receptor kinase (Trk) inhibitor to study the role of TrkA signaling in rats as a Trk inhibitor for inducing in vitro injury in retinal MÃ¼ller glial cells to study the effects of cord blood serum

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

Application

K-252a has been used:

as a tropomyosin receptor kinase (Trk) inhibitor to study the role of TrkA signaling in rats
as a Trk inhibitor for inducing in vitro injury in retinal MÃ¼ller glial cells to study the effects of cord blood serum (CBS)
as a general protein kinase inhibitor to study its effect on in vitro human somatic testicular cell reassembly

Biochem/physiol Actions

K-252a is a selective inhibitor of tyrosine protein kinase. It targets a wide range of protein kinases with IC₅₀ values between 3 and 25nM and the neurotrophin receptor-tropomyosin receptor kinase.

UPC:: 51172827
Condition:: New
Weight:: 1.00 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: K1639-100UG

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."